Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 10 | 2024 | 105 | 2.270 |
Why?
|
| Prostatic Neoplasms | 12 | 2024 | 1751 | 2.080 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2023 | 419 | 1.310 |
Why?
|
| Anilides | 2 | 2020 | 45 | 1.260 |
Why?
|
| Pyridines | 2 | 2020 | 303 | 1.100 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2023 | 138 | 0.910 |
Why?
|
| Retinal Neoplasms | 1 | 2023 | 11 | 0.860 |
Why?
|
| Retinoblastoma | 1 | 2023 | 28 | 0.860 |
Why?
|
| Immunotherapy | 2 | 2018 | 702 | 0.830 |
Why?
|
| Neutrophils | 2 | 2020 | 313 | 0.770 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 478 | 0.740 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2020 | 159 | 0.680 |
Why?
|
| Nanoparticles | 1 | 2020 | 165 | 0.640 |
Why?
|
| Androgen Antagonists | 5 | 2024 | 138 | 0.600 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 38 | 0.560 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 16 | 0.560 |
Why?
|
| Precision Medicine | 3 | 2020 | 414 | 0.520 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2409 | 0.500 |
Why?
|
| Biomedical Research | 1 | 2018 | 403 | 0.450 |
Why?
|
| Mice | 11 | 2023 | 11949 | 0.410 |
Why?
|
| Male | 22 | 2024 | 42967 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 269 | 0.360 |
Why?
|
| Germ-Line Mutation | 3 | 2020 | 349 | 0.310 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 2609 | 0.310 |
Why?
|
| Animals | 12 | 2023 | 27715 | 0.280 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 4 | 2021 | 76 | 0.280 |
Why?
|
| Indoles | 4 | 2023 | 306 | 0.280 |
Why?
|
| Humans | 24 | 2024 | 90640 | 0.260 |
Why?
|
| Neoplasms | 2 | 2018 | 3030 | 0.240 |
Why?
|
| Proteomics | 2 | 2023 | 242 | 0.240 |
Why?
|
| Lactates | 1 | 2023 | 36 | 0.220 |
Why?
|
| Lead | 1 | 2023 | 28 | 0.220 |
Why?
|
| Phagocytosis | 1 | 2023 | 86 | 0.220 |
Why?
|
| Macrophages | 2 | 2023 | 585 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 98 | 0.210 |
Why?
|
| beta Catenin | 1 | 2023 | 267 | 0.190 |
Why?
|
| Genetic Testing | 3 | 2021 | 544 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2023 | 3431 | 0.190 |
Why?
|
| Androgens | 3 | 2024 | 175 | 0.180 |
Why?
|
| Butyrophenones | 1 | 2020 | 5 | 0.180 |
Why?
|
| Histamine H1 Antagonists | 1 | 2020 | 40 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 37 | 0.180 |
Why?
|
| Receptors, Androgen | 2 | 2022 | 119 | 0.170 |
Why?
|
| NF-kappa B | 1 | 2023 | 469 | 0.170 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 161 | 0.160 |
Why?
|
| Piperidines | 1 | 2020 | 163 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 493 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 205 | 0.160 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 1806 | 0.150 |
Why?
|
| Benzylamines | 1 | 2017 | 17 | 0.140 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 17 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2525 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 167 | 0.130 |
Why?
|
| Androstenes | 1 | 2016 | 39 | 0.130 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1695 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 107 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 2 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 53 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 253 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 17 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2017 | 437 | 0.110 |
Why?
|
| Glutamine | 1 | 2013 | 81 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 589 | 0.100 |
Why?
|
| Glucose | 2 | 2013 | 635 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 610 | 0.100 |
Why?
|
| Metformin | 1 | 2013 | 132 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2011 | 49 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 38 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2024 | 342 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 152 | 0.090 |
Why?
|
| Lipogenesis | 1 | 2010 | 24 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 65 | 0.080 |
Why?
|
| DNA Damage | 2 | 2023 | 374 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2008 | 281 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1066 | 0.060 |
Why?
|
| Mutation | 2 | 2022 | 4183 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 280 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2024 | 11 | 0.060 |
Why?
|
| Castration | 1 | 2024 | 37 | 0.060 |
Why?
|
| Prednisone | 1 | 2024 | 254 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 95 | 0.050 |
Why?
|
| Testosterone | 1 | 2024 | 272 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 103 | 0.050 |
Why?
|
| Genes, BRCA2 | 1 | 2023 | 161 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 342 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2020 | 60 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 130 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6816 | 0.040 |
Why?
|
| Diarrhea | 1 | 2020 | 178 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1583 | 0.040 |
Why?
|
| Pneumonia | 1 | 2020 | 184 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 62 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2019 | 102 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 854 | 0.040 |
Why?
|
| Leuprolide | 1 | 2016 | 35 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 349 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 260 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 491 | 0.030 |
Why?
|
| Models, Biological | 2 | 2013 | 1770 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2891 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 101 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 24 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2013 | 61 | 0.030 |
Why?
|
| Phenylthiohydantoin | 1 | 2013 | 46 | 0.030 |
Why?
|
| Aged | 2 | 2020 | 19424 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 156 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 282 | 0.030 |
Why?
|
| Benzamides | 1 | 2013 | 236 | 0.020 |
Why?
|
| Prostate | 1 | 2016 | 408 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 397 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1056 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4348 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 26347 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2670 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 183 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1286 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 135 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 125 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 189 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2010 | 287 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 388 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8379 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1725 | 0.020 |
Why?
|
| Obesity | 1 | 2010 | 979 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2337 | 0.010 |
Why?
|
| Female | 1 | 2020 | 46894 | 0.010 |
Why?
|